Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study

Ping Li¹, Hongyan Zhang², Caidong Luo³, Zheng Ji⁴, Zeqi Zheng⁵, Zhenyong Li⁶, Fan Wu⁷, Jinlong Li⁸* and Lang Hong⁹*

¹Department of Cardiology, The First People’s Hospital of Yulin, Yulin, China, ²Department of Cardiology, Affiliated Hospital of Qilu Medical University (The People’s Hospital of Xin Tai City), Xintai, China, ³Department of Cardiology, Mianyang Central Hospital, Mianyang, China, ⁴First Department of Cardiology, Tangshan Workers’ Hospital, Tangshan, China, ⁵Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, China, ⁶Department of Cardiology, Xuzhou Central Hospital, Xuzhou, China, ⁷Second Department of Cardiology, Xuchang Central Hospital, Xuchang, China, ⁸Department of Cardiology, The Affiliated Taian City Central Hospital of Qingdao University, Tai’an, China, ⁹Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

Background: Bivalirudin is a common anticoagulant during percutaneous coronary intervention (PCI); however, since its application in China, it still lacks comprehensive evaluation of adverse events (AEs) or adverse drug reactions (ADRs) under the real-clinical setting conditions with a large-sample-size population. Therefore, this prospective, multi-center, intensive monitoring study aimed to comprehensively investigate the occurrence and risk factors of AEs and ADRs during PCI with bivalirudin as an anticoagulant.

Methods: A total of 3,049 patients who underwent PCI with bivalirudin as anticoagulant from 27 Chinese medical centers were enrolled. Safety data (AEs/ADRs) were collected from hospital admission to 72 h after bivalirudin administration; then, patients were followed up at the 30th day with the safety data collected as well.

Results: A total of 414 (13.58%) patients occurred AEs, among which 31 (1.02%) cases suffered from severe AEs and 8 (0.26%) cases died due to AEs. Importantly, 118 (3.87%) patients occurred bivalirudin related ADRs, among which 7 (0.23%) cases suffered from severe ADRs while no case (0%) died due to ADRs. Of note, 7 (0.23%) patients showed new ADRs, 34 (1.12%) patients experienced bleeding, and 79 (2.59%) patients had thrombocytopenia. Furthermore, age, renal function impairment, CRUSADE high risk stratification independently correlated with total ADRs risk; CRUSADE high risk stratification,
INTRODUCTION

Cardiovascular disease, as the most common cause of mobility and mortality, is a critical issue affecting global human health (1). Pleasingly, along the introduction and advancement of percutaneous coronary intervention (PCI), the outcomes and long-term prognosis of patients with cardiovascular disease have been improved a lot, while its concomitant complications still worry the physicians and patients (2, 3). Among PCI-related complications, thrombotic complication such as stent thrombosis, is one of the prior concerns to be handled; then for years, unfractionated heparin (UFH) (with or without glycoprotein IIb/IIIa inhibitors) was considered as the anticoagulant choice during PCI, while it exhibits several limits: unpredictability of biological efficiency, platelets activation, heparin-induced thrombocytopenia, and bleeding (4–7). Therefore, exploration of better adjunctive anticoagulant during PCI is of great importance.

Bivalirudin, a synthetic analog of natural anticoagulant hirudin which consists of 20 amino acid peptides, is an explicit and irreversible thrombin inhibitor with concentration-dependent competitive and non-competitive thrombin repressing effect (8, 9). Unlike the UFH, bivalirudin not only realizes expectable anticoagulant outcome with linear pharmacokinetic and pharmacodynamic properties, it also achieves quicker onset and has a shortened action period; but also reduces the influence of platelet function and bleeding, which makes it a potentially alternative option for anticoagulant during PCI (8–12). Clinically, several randomized trials have demonstrated the non-inferiority of bivalirudin vs. UFH plus glycoprotein IIb/IIIa inhibitors regrading ischemic events, but the superiority of lower bleeding risk in PCI procedures as anticoagulant (6, 12–14). However, since its application in China, it still lacks comprehensive evaluation of adverse events (AEs) or adverse drug reactions (ADRs) under the real-clinical setting conditions with a larger-sample-size population, especially for the exploration of severe, rare, or new ones; furthermore, identification of their risk factors is deficient as well.

Therefore, the current prospective, multi-center, intensive monitoring study enrolled 3,049 patients who underwent PCI with bivalirudin as anticoagulant from 27 Chinese medical centers, then aimed to comprehensively investigate the occurrence and risk factors of AEs and ADRs, especially for bleeding and thrombocytopenia.

METHODS

Study Design

This was a prospective, multi-center, intensive monitoring study. The case enrollment and information collection of this study were carried out in 27 Chinese medical centers (shown in Supplementary Table 1). In the whole process of the study, the medication use and treatment of patients were determined by attending physicians according to the actual clinical situation, which were not interfered by the study. This study was approved by the Ethics Committee of each participant center with those of Beijing Anzhen Hospital Affiliated to Capital Medical University (approval number: KS2019012) and Peking University People's Hospital (approval number: 2018PHA092-001) as the primary Ethics Committees.

Patient Enrollment

This study was conducted between July 2018 and June 2019. To observe a 0.1% incidence of ADRs (that was, ARDs occurred in at least one or more cases), the required sample size was 3,000, with a power of 95%. A total of 3,050 patients were recruited, among which, one patient was excluded subsequently due to that the patient only received an angiography without PCI. Finally, 3,049 patients who underwent PCI with bivalirudin used as anticoagulant in the 27 medical centers were enrolled and analyzed in the current study. The inclusion criteria were: (1) underwent PCI or percutaneous coronary angioplasty (PTCA); (2) using bivalirudin as anticoagulant; (3) age over 18 years; (4) understand the study content and voluntarily participated in the study. Patients without use of bivalirudin were excluded from the study.

Clinical Data Collection

Clinical data were collected after hospital admission. The mainly collected data covered the following: (1) basic information: age, gender, height, and weight; (2) medical history: allergy, cardiac surgery, critical respiratory disease, diabetes or thrombolysis, and tumor; (3) renal function impairment and severity; (4) clinical features: clinical presentation, CRUSADE score (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines), and CRUSADE risk stratification; (5) PCI-related information: timing limitation of operation (emergency or elective), types of coronary interventional therapy, arterial access, operative time, and time of bivalirudin infusion; (6) treatment: full-dose use of bivalirudin, and glycoprotein IIb/IIIa inhibitor...
use; (7) Thrombolysis in Myocardial Infarction (TIMI) grade: pre-procedure TIMI grade, and post-procedure TIMI grade.

Safety Data Collection
Safety data were collected from hospital admission to 72 h after completion of bivalirudin administration. In addition, patients were followed up at the 30th day, and the data were also collected at that time. The primary safety data included any AEs, which were required to be documented in detail during the period of intensive monitoring. Classification of AEs was coded using the Systematic Organ Classification (SOC) and Preferred Term (PT) of the International Conference on the Coordination of International Drug Registration (ICH) International Dictionary of Medical Terms (MedDRA) 23.0. The intensive monitoring ADRs were bleeding and thrombocytopenia, among which, the bleeding was graded in terms of Bleeding Academic Research Consortium (BARC) consensus classification criteria (15). All the summaries of AEs were based on cases. If a case suffered from the same AE repeatedly, the severity of the AE was calculated according to the most serious one.

Definitions
AEs were defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment that may or may not be considered related to the medical treatment. Severe adverse events (SAEs) were defined as one of the following events: (1) leading to death; (2) life-threatening consequences; (3) leading to carcinogenesis, teratogenesis, and birth defects; (4) leading to significant or permanent human disability or organ function damage; (5) resulting in hospitalization or prolonged length of stay; (6) leading to other important medical events, if not treated, the above-listed conditions may occur. ADRs were defined as the harmful reaction of qualified drugs which was irrelevant to the purpose of medication under normal usage and dosage. New ADRs were defined as the adverse reactions not specified in the drug instructions. Moreover, if the nature, extent, consequence, or frequency of adverse reactions were inconsistent with the drug instructions but more serious than those described in the instructions, they were also regarded as new ADRs.

Statistical Analysis
SAS 9.4 (SAS Institute, Inc., Cary, NC) was applied to complete data analysis. Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were described as times, numbers, and percentages, as well as 95% confidence intervals (CI). Summary of AEs and ADRs was presented as number of times, incidence rate, and 95%CI. Detailed AEs, ADRs, and new ADRs in SOC were described as the number of times and incidence rate. Incidence of ADRs (Figure 1), bleeding events (Figure 2), and thrombocytopenia (Figure 3) in different populations was checked by Chi-square test or Fisher’s exact test (when the expected count was less than 5). The crude odds ratio (OR) in Figures 1–3 was estimated by univariate logistic regression model analysis, and the corresponding adjusted OR was estimated by multivariate logistic regression model analysis with all variables included in, which were shown in a forest plot. A P < 0.05 was regarded as significant significance.

RESULTS
Characteristics of Patients and PCI Procedure
The enrolled patients exhibited a mean age of 64.78 ± 11.39 years with 2,131 (69.89%) males and 918 (30.11%) females. There were 1,244 (40.81%), 414 (13.58%), 1,034 (33.91%), and 352 (11.54%) patients who showed clinical presentation of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTMI), unstable angina (UA), and spontaneous coronary artery dissection (SCAD), respectively; while 5 (0.16%) showed unknown clinical presentation. Furthermore, CRUSADE risk stratification identified 722 (23.68%), 1,014 (33.26%), 729 (23.91%), 342 (11.22%), 194 (6.36%), and 48 (1.57%) as very low risk, low risk, moderate risk, high risk, very high risk, and unknown risk, respectively. The detailed characteristics of patients are shown in Table 1.

Regarding the characteristics of PCI, 1,351 (44.31%) performed emergency operation while 1,698 (55.69%) performed elective operation. Operative duration and duration of bivalirudin infusion were 69.60 ± 48.00 min and 91.15 ± 77.40 min, respectively. Besides, 1,942 (63.69%) and 2,221 (72.84%) had full-dose use of bivalirudin and glycoprotein IIb/IIIa inhibitor use, respectively. The detailed characteristics of the PCI procedure are shown in Supplementary Table 2. Furthermore, so as to clearly present the clinical administration of bivalirudin in the current study, the detailed information was also listed (Supplementary Table 3).

General Information of AEs and ADRs
A total of 414 (13.58%) patients occurred AEs, among which 31 (1.02%) cases suffered from SAEs and 8 (0.26%) cases died due to AEs (Table 2). Importantly, regarding bivalirudin, a total of 118 (3.87%) patients occurred ADRs, among which 7 (0.23%) cases suffered from SADRs while no case (0%) died due to ADRs (Table 2). Furthermore, 7 (0.23%) patients showed new ADRs of bivalirudin, 34 (1.12%) patients experienced bleeding, and 79 (2.59%) patients had thrombocytopenia.

Detailed AEs and ADRs Categorized by System Organ Class (SOC)
The most common AEs were gastrointestinal disorders (3.58%), general disorders and administration site conditions (3.31%), respiratory, thoracic, and mediastinal disorders (3.18%), then blood and lymphatic system disorders (2.66%) (Supplementary Table 4). Meanwhile, the most prevalent ADRs of bivalirudin were blood and lymphatic system disorders (2.62%), gastrointestinal disorders (0.69%), investigations (0.20%), then respiratory, thoracic, and mediastinal disorders (0.16%) (Table 3). Specifically, the detailed information of total bleeding events and bleeding events related to bivalirudin are presented in
Supplementary Table 5. In addition, 6 patients experienced one new ADR and 1 patient faced two new ADRs, resulting in 7 (0.23%) patients suffering from new ADRs (Supplementary Table 6). The detailed information of AEs, ADRs, and new ADRs could be referred to Table 3 and Supplementary Tables 4, 6, respectively.
Risk Factors Related to ADRs
Univariate logistic regression model identified that age (>75 years), history of diabetes or thrombolysis, renal function impairment (moderate or severe), and CRUSADE high risk stratification correlated with increased ADRs occurrence (Figure 1). Then after adjustment by multivariate logistic regression model, age (>75 years) (OR 1.71, 95%CI 1.08–2.69; \(P = 0.022\)), renal function impairment (moderate OR 1.91, 95%CI 1.03–3.55; \(P = 0.041\)) (severe OR 3.17, 95%CI 1.34–7.50; \(P = 0.009\)), and CRUSADE high risk stratification (OR 1.77, 95%CI 1.07–2.94; \(P = 0.027\)) were discovered to dependently relate to ADRs occurrence (Figure 1).

Risk Factors of Bivalirudin Related Bleeding Events
Univariate logistic regression model disclosed that age (>75 years), moderate renal function impairment, CRUSADE high risk stratification, operative timing (emergency vs. elective), and full dose use of bivalirudin in STEMI patients correlated with increased bivalirudin related bleeding events occurrence (Figure 2). After adjustment by multivariate logistic regression model, CRUSADE high risk stratification (OR 4.01, 95%CI 1.55–10.36; \(P = 0.004\)), operative timing (emergency vs. elective) (OR 3.41, 95%CI 1.35–8.61; \(P = 0.009\)), full dose use of bivalirudin (STEMI patients OR 7.77, 95%CI 1.59–38.11; \(P = 0.011\)) (Non-STEMI patients OR 9.51, 95%CI 1.96–46.00; \(P = 0.005\)) independently correlated with increased bivalirudin related bleeding events occurrence (Figure 2).

Risk Factors of Bivalirudin Related Thrombocytopenia
Univariate logistic regression model exhibited that age (>75 years), history of cardiac surgery, history of diabetes or thrombolysis, history of tumor, renal function impairment (mild, moderate, or severe vs. no), CRUSADE high risk stratification, and radial artery access correlated with thrombocytopenia risk (Figure 3). Post adjustment via multivariate logistic regression model, only age (>75 years) (OR 1.95, 95%CI 1.15–3.30; \(P = 0.013\)) and renal function impairment (severe OR 4.41, 95%CI 1.70–11.46; \(P = 0.002\)) were independently associated with elevated thrombocytopenia risk (Figure 3).

DISCUSSIONS
Accumulating reports demonstrate that anticoagulant use of bivalirudin during PCI is of very good tolerance, while some minor AEs or ADRs still need attention, such as bleeding (especially major bleeding), cardiac/cardiovascular events (such as heart failure, cardiogenic shock, recurrent myocardial infarction, etc.), cerebrovascular events (such as stroke, etc.), stent thrombosis, and so on (16–21). It was reported that bleeding events occur in 5.0–11.3% patients, among which major bleeding events affect 0.9–7.8% patients who are undergoing PCI with bivalirudin as anticoagulant (16, 19, 22). Furthermore, safety related major adverse cardiac events (MACEs) appear in 7.6–13.4% patients (17, 19); safety related stroke events happen in 0.2–1.7% patients who perform bivalirudin-involving
TABLE 1 | Clinical characteristics of participants.

| Parameters                                             | Patients (N = 3,049) |
|--------------------------------------------------------|----------------------|
| Age (years), mean ± SD                                  | 64.78 ± 11.39        |
| Gender, No. (%)                                         |                      |
| Male                                                   | 2,131 (69.89)        |
| Female                                                 | 918 (30.11)          |
| Height (cm)                                             |                      |
| Assessable, No. (%)                                     | 2,852 (93.54)        |
| Mean ± SD                                              | 165.25 ± 8.28        |
| Weight (kg)                                             |                      |
| Assessable, No. (%)                                     | 2,995 (98.22)        |
| Mean ± SD                                              | 66.35 ± 11.56        |
| History of allergy, No. (%)                            | 274 (8.99)           |
| History of cardiac surgery, No. (%)                    | 283 (9.28)           |
| History of critical respiratory disease, No. (%)       | 109 (3.57)           |
| History of diabetes or thrombolysis, No. (%)           | 2,584 (84.75)        |
| History of tumor, No. (%)                              | 35 (1.15)            |
| Renal function impairment, No. (%)                     |                      |
| No                                                      | 1,592 (52.21)        |
| Mild                                                    | 1,020 (33.45)        |
| Moderate                                                | 328 (10.76)          |
| Severe                                                  | 75 (2.46)            |
| Unknown                                                 | 34 (1.12)            |
| Clinical presentation, No. (%)                         |                      |
| STEMI                                                   | 1,244 (40.81)        |
| NSTEMI                                                  | 414 (13.58)          |
| UA                                                      | 1,034 (33.91)        |
| SCAD                                                    | 352 (11.54)          |
| Unknown                                                 | 5 (0.16)             |
| CRUSADE score                                           |                      |
| Assessable, No. (%)                                     | 3,001 (98.43)        |
| Mean ± SD                                              | 29.42 ± 13.09        |
| CRUSADE risk stratification, No. (%)                   |                      |
| Very low risk                                           | 722 (23.68)          |
| Low risk                                                | 1,014 (33.26)        |
| Moderate risk                                           | 729 (23.91)          |
| High risk                                               | 342 (11.22)          |
| Very high risk                                          | 194 (6.38)           |
| Unknown                                                 | 48 (1.57)            |

SD, standard deviation; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina; SCAD, spontaneous coronary artery dissection; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines.

TABLE 2 | Summary of AEs and ADRs.

| Items                                      | Number of times | Incidence, no. (%) | 95% CI of incidence |
|--------------------------------------------|-----------------|--------------------|---------------------|
| Adverse events (AEs)                       |                 |                    |                     |
| Total AEs                                  | 829             | 414 (13.58)        | 12.38–14.84         |
| SAEs                                       | 38              | 31 (1.02)          | 0.69–1.44           |
| Death due to AEs                           | 9               | 8 (0.26)           | 0.11–0.52           |
| Adverse drug reactions (ADRs)              |                 |                    |                     |
| Total ADRs                                 | 130             | 118 (3.87)         | 3.21–4.62           |
| SADRs                                      | 7               | 7 (0.23)           | 0.09–0.47           |
| Death due to ADRs                          | 0               | 0 (0.00)           | –                   |
| New ADRs                                   | 8               | 7 (0.23)           | 0.09–0.47           |
| Bleeding                                   | 37              | 34 (1.12)          | 0.77–1.55           |
| BARC type 0                                | 1               | 1 (0.03)           | 0.00–0.18           |
| BARC type 1                                | 29              | 27 (0.89)          | 0.58–1.29           |
| BARC type 2                                | 2               | 2 (0.07)           | 0.01–0.24           |
| BARC type 3a                               | 5               | 4 (0.13)           | 0.04–0.34           |
| Thrombocytopenia                           | 79              | 79 (2.59)          | 2.06–3.22           |

AEs, adverse events; SAEs, severe adverse events; ADRs, adverse drug reactions; SADRs, severe adverse drug reactions; BARC, Bleeding Academic Research Consortium; CI, confidence interval.

In order to provide the precise and strict information about the adverse events/adverse reactions related to bivalirudin application as anticoagulant during PCI for further drug choice guiding, we evaluated ADRs of bivalirudin during PCI, which were defined as the harmful reaction of qualified drugs that was irrelevant to the purpose of medication under normal usage and dosage. It was discovered that 3.87% patients experienced bivalirudin related ADRs, among which 0.23% cases suffered from SADRs, while no case died due to ADRs. However, there has been no previous study analyzing the bivalirudin related ADRs during PCI. This current study is the first to provide the overall information about it (16–23). Generally speaking, we observed that bivalirudin was well-tolerated as an anticoagulant for PCI. Then to identify potential risk factors of ADRs induced by bivalirudin during PCI, logistic regression analysis was performed which discovered that older age, renal
function impairment, and CRUSADE high risk stratification independently correlated with ADRs occurrence. The possible explanations were as follows: (1) Patients with older age might have more complications and worse metabolism ability for drugs, leading to increased ADRs (24, 25); (2) renal function impairment affected the drug metabolism directly, which resulted in ADRs (26); (3) CRUSADE high risk stratification reflected higher possibility of bleeding, which was one of the most common ADRs of bivalirudin. In the current study, one patient died of acute heart failure, two patients died of acute myocardial infarction, two patients died of tachycardia, one patient died of hypotension, one patient died of hypoxemia, and two patients died of systematic syndromes. After assessment, it is considered that none of these patients died of bivalirudin-related adverse reactions.

Furthermore, 0.23% patients showed new ADRs of bivalirudin, 1.12% patients experienced bivalirudin related bleeding, and 2.59% patients had bivalirudin related thrombocytopenia during PCI. These informed us that the occurrence of bleeding and thrombocytopenia, directly induced by bivalirudin, were less than the previous opinions (16, 19, 22). Moreover, apart from CRUSADE high risk stratification, operative timing (emergency vs. elective), and full dose use of bivalirudin also independently correlated with increased bivalirudin related bleeding events risk during PCI. These might result from: (1) an emergency operation reflected the acute and severe disease condition or short preparation time for complication prevention therefore led to increased bleeding risk; (2) full dose vs. reduced dose use of bivalirudin suggested the increased anticoagulant effect, generating increased bleeding possibility. When looking at thrombocytopenia, older age and renal function impairment were independently associated with its increased risk, with the possible explanations the same as their contributions to total ADRs risk (24–26). In addition, it is of note that a previous HEAT-PPCI study observes that bivalirudin does not decrease bleeding risk while increases acute stent thrombosis risk compared to UFH in STEMI patients (27). However, it brings about great dispute resulting from the following issues: (1) HEAT-PPCI is a single-center study; (2) the assessment of AEs by a third party is not carried out; and (3) activated clotting time (ACT) during operation is quite accidentally lower compared to previous studies. The findings of this study confirmed that bivalirudin as an anti-coagulant during PCI was a safe regimen. Meanwhile, the recognition of risk factors related to ADRs, bleeding, and thrombocytopenia might help to improve the administration of bivalirudin as anti-coagulant during PCI.

Despite these interesting findings, the current study still faces some limitations. First, the sample size of this study was calculated and set to 3,049 based on the purpose to observe the ADR with at least 0.1% incidence, while some SADRs or even deadly ADRs might not be easily discovered in this study. Hence, an even larger sample size population study would be needed in the future. Second, the medical centers participating in this study were almost first-class hospitals in China which could not represent all-level hospitals, therefore the physicians’ skill and patients’ bias would exist. Third, since the total ADRs, especially bivalirudin related bleeding events and bivalirudin related thrombocytopenia, rarely occurred, the risk factors analyzed by logistic regression analysis might have relatively low statistical power. Fourth, a long-term follow-up could be conducted to explore the safety of bivalirudin.

**CONCLUSION**

In conclusion, bivalirudin is well-tolerated as anticoagulant for a PCI procedure; meanwhile, older age, renal function impairment, and CRUSADE high risk stratification serve as independent risk factors of bivalirudin related ADRs.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Beijing Anzhen Hospital Affiliated to Capital Medical University (K2019012) and Peking University People's Hospital (2018PHA092-001). The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. (2019) 381:1557–67. doi: 10.1056/NEJMra1806939
2. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2013) 61:e78–140. doi: 10.1016/j.jacc.2012.11.019
3. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr., Ganiats TG, Holmes DR Jr., et al. AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2014) 64:e139–228. doi: 10.1016/j.jacc.2014.09.017
4. Saito Y, Kobayashi Y. Update on antithrombotic therapy after percutaneous coronary intervention. Intern Med. (2020) 59:311–21. doi: 10.2169/internalmedicine.3685-19
5. Mahmoud A, Saad M, Elgendy AY, Abuzaid A, Elgendy IY. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice? Cardiovasc Ther. (2015) 33:227–35. doi: 10.1111/1755-5922.12124
6. Ahmad Hamdi AH, Dali AF, Mat Nuri TH, Saleh MS, Ajmi NN, Neoh CF, et al. Safety and effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Front Pharmacol. (2017) 8:410. doi: 10.3389/fphar.2017.00410
7. Laine M, Lemesle G, Dabry T, Panagides V, Peyrol M, Paganelli F, et al. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. Expert Opin Pharmacother. (2019) 20:295–304. doi: 10.1080/14656566.2018.1551361
8. Li S, Lv D, Liu C, Jia Y. Practicability of bivalirudin plus glycoprotein iiib/iiiia inhibitors in patients undergoing percutaneous coronary intervention: A meta-analysis. Clin Appl Thromb Hemost. (2021) 27:107602962011055165. doi: 10.1177/107602962011055165
9. Shammas NW. Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. (2005) 23:345–60. doi: 10.1111/j.1527-3466.2005.tb00177.x
10. Kolotwski L, Legutko J, Filipiak KJ, Dziewierz A, Bartus S, Buszman P, et al. Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. Cardiol J. (2019) 26:1–7. doi: 10.5603/CJ.2019.0029
11. Androue C, Maniotis C, Koutouzis M. The rise and fall of anticoagulation with bivalirudin during percutaneous coronary interventions: a review article. Cardiol Ther. (2017) 6:1–12. doi: 10.1007/s40191-017-0082-x
12. Nuhrenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin Res Cardiol. (2018) 107:807–15. doi: 10.1007/s00392-018-1251-1
13. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. (2008) 358:2218–30. doi: 10.1056/NEJMoa0708191
14. Wang H, Li Y, Cong H, Ding S, Liu B, Li L, et al. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: a subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial. Catheter Cardiovasc Interv. (2017) 89:156–65. doi: 10.1002/cct.26804
15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. (2011) 123:2736–47. doi: 10.1161/CIRCULATIONAHA.110.009449
16. Dauerman HL, Frederick PD, Miller D, French WJ, National Registry of Myocardial Infarction I. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis. (2007) 18:141–8. doi: 10.1097/MCA.0b013e32801c4ab2
17. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein iiib/iiiia inhibitor versus bivalirudin monotherapy and paxilxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. (2011) 377:2193–204. doi: 10.1016/S0140-6736(11)60764-2
18. Stone GW, Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). J Am Coll Cardiol. (2014) 63:15–20. doi: 10.1016/j.jacc.2013.09.027
19. Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Catheter Cardiovasc Interv. (2010) 76:513–24. doi: 10.1002/cdi.22346
20. Kong LD, Wang G, Han YL, Li G, Li XY, Liu ZX, et al. [Efficacy of periprocedural bivalirudin infusion in patients with chronic total occlusion lesion undergoing percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi. (2018) 46:543–48. doi: 10.3760/cma.j.issn.0253-3758.2018.07.007

AUTHOR CONTRIBUTIONS

PL and HZ made substantial contributions to the design of the present study. Data acquisition and interpretation were performed by PL, HZ, CL, ZJ, ZZ, ZL, FW, JL, and LH. PL, HZ, JL, and LH critically revised the manuscript for important intellectual content. All authors approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.781632/full#supplementary-material
21. Xiang DC, Gu XL, Song YM, Huang WJ, Tang LQ, Yin YH, et al. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention. *Chin Med J.* (2013) 126:3064–8.
22. Lincoff AM, Mehran R, Povsic TJ, Zelenkofose SL, Huang Z, Armstrong PW, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. *Lancet.* (2016) 387:349–56. doi: 10.1016/S0140-6736(15) 00515-2
23. MacHaalany J, Abdelaal E, Bataille Y, Plourde G, Duranleau-Gagnon P, Larose E, et al. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention. *Am J Cardiol.* (2012) 110:1742–8. doi: 10.1016/j.amjcard.2012. 07.043
24. Trevisan A, Nicolli A, Chiara F. Are rats the appropriate experimental model to understand age-related renal drug metabolism and toxicity? *Expert Opin Drug Metab Toxicol.* (2010) 6:1451–9. doi: 10.1517/17425255.2010. 531701
25. Khan MR, Kayani WT, Ahmad W, Manan M, Hira RS, Hamzeh I, et al. Effect of increasing age on percutaneous coronary intervention vs coronary artery bypass grafting in older adults with unprotected left main coronary artery disease: a meta-analysis and meta-regression. *Clin Cardiol.* (2019) 42:1071–78. doi: 10.1002/clc.23253
26. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). *Am J Cardiol.* (2005) 95:581–5. doi: 10.1016/j.amjcard.2004.11.003
27. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. *Lancet.* (2014) 384:1849–58. doi: 10.1016/S0140-6736(14)60924-7

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.